Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male volunteers~* Subjects aged 18 - 45 years~* Subjects weighing ≥ 50.0 kg and ≤ 100.0 kg~* Subjects with a body mass index (BMI) ≥ 19.0 and ≤ 26.0 kg/m2~Exclusion Criteria:~* Subjects with evidence or history of clinically significant disease~* Subjects with a history of previous cancer~* Subjects with a history of hypertension, or abnormal blood pressure at screening/baseline measurements (systolic blood pressure \> 140 mmHg and/or diastolic blood pressure \> 90 mmHg confirmed by a repeat measurement on the same day)~* Subjects with a history of blood donation 3 months before study drug infusion~* Subjects with a history of exposure to antibodies 12 months before study drug infusion~* Subjects with previous exposure to anti-VEGF therapy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- LY01008 (Type: EXPERIMENTAL): Single intravenous injection of LY01008 3 mg/kg for 90 min(±1 min).
- Avastin (Type: ACTIVE_COMPARATOR): Single intravenous injection of Avastin 3 mg/kg for 90 min(±1 min).

Based on this trial design, predict the completion outcome and termination type (if applicable).